Calamos Advisors’s Nutex Health NUTX Stock Holding History

Calamos Advisors’s Portfolio NUTX Stock Details NUTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,947	Closed	-$242K	–	978
2025 Q2	$242K	Buy	+1,947	New	+$252K	﹤0.01%	811

Other funds holding NUTX

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Calamos Advisors's NUTX Position: Q3 2025 in Review

Calamos Advisors sold out of Nutex Health (NUTX) in Q3 2025, closing a stake of 1,947 shares — an estimated $242K sold.

Calamos Advisors first reported a position in NUTX in Q2 2025 and held it in 1 quarter. The position peaked at $242K in Q2 2025. 95 funds tracked by Wall St. Rank hold NUTX as of Q3 2025.

Calamos Advisors reported no remaining Nutex Health position as of Q3 2025 after selling out during the quarter.
Calamos Advisors sold 1,947 Nutex Health shares in Q3 2025, an estimated $242K.
Calamos Advisors first reported a position in Nutex Health in Q2 2025 and held it in 1 quarter.
Calamos Advisors's Nutex Health position peaked at $242K in Q2 2025.
95 funds tracked by Wall St. Rank held Nutex Health as of Q3 2025.

Based on Calamos Advisors's 13F filing for Q3 2025, filed 20 Oct 2025.